These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 28641169)

  • 41. Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).
    Rahman MM; Alatawi Y; Cheng N; Qian J; Plotkina AV; Peissig PL; Berg RL; Page D; Hansen RA
    Epilepsy Res; 2017 Sep; 135():71-78. PubMed ID: 28641219
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication.
    Johannessen Landmark C; Baftiu A; Tysse I; Valsø B; Larsson PG; Rytter E; Johannessen SI
    Ther Drug Monit; 2012 Aug; 34(4):440-5. PubMed ID: 22777154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Antiepileptic drugs in North America].
    Akiyama T; Otsubo H
    Brain Nerve; 2010 May; 62(5):519-26. PubMed ID: 20450099
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures.
    Berg MJ; Gross RA; Tomaszewski KJ; Zingaro WM; Haskins LS
    Neurology; 2008 Aug; 71(7):525-30. PubMed ID: 18695164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M
    Epilepsia; 2007 Oct; 48(10):1825-32. PubMed ID: 17850324
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis.
    Costa J; Fareleira F; Ascenção R; Borges M; Sampaio C; Vaz-Carneiro A
    Epilepsia; 2011 Jul; 52(7):1280-91. PubMed ID: 21729036
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An investigation of the characteristics of outpatients with epilepsy and antiepileptic drug utilization in a multicenter cross-sectional study in China.
    Yu P; Zhou D; Liao W; Wang X; Wang Y; Wang T; Wu Y; Lang S; Lin W; Song Y; Zhao H; Cai M; Hong Z
    Epilepsy Behav; 2017 Apr; 69():126-132. PubMed ID: 28242476
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact on health outcomes and healthcare utilisation of switching to generic medicines consequent to reference pricing: the case of lamotrigine in New Zealand.
    Lessing C; Ashton T; Davis P
    Appl Health Econ Health Policy; 2014 Oct; 12(5):537-46. PubMed ID: 25005492
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Generic drugs in the treatment of epilepsy].
    González de Dios J; Ochoa-Sangrador C; Sempere AP
    Rev Neurol; 2005 Dec 1-15; 41(11):676-83. PubMed ID: 16317637
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antiepileptic Drugs.
    Abou-Khalil BW
    Continuum (Minneap Minn); 2016 Feb; 22(1 Epilepsy):132-56. PubMed ID: 26844734
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability, and formulation switches using Monte Carlo simulations.
    Karalis V; Macheras P; Bialer M
    CNS Drugs; 2014 Jan; 28(1):69-77. PubMed ID: 24092569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of generic switching on concerns about medicine and non-persistence among Danish adults in a general practice setting.
    Rathe JØ
    Dan Med J; 2015 Oct; 62(10):B5148. PubMed ID: 26441397
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.
    Fishman J; Kalilani L; Song Y; Swallow E; Wild I
    J Manag Care Spec Pharm; 2018 Sep; 24(9):929-938. PubMed ID: 29486142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Specific adverse effects of antiepileptic drugs--A true-to-life monotherapy study.
    Kowski AB; Weissinger F; Gaus V; Fidzinski P; Losch F; Holtkamp M
    Epilepsy Behav; 2016 Jan; 54():150-7. PubMed ID: 26709103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
    Zachry WM; Doan QD; Clewell JD; Smith BJ
    Epilepsia; 2009 Mar; 50(3):493-500. PubMed ID: 18616554
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam.
    Mula M; Trimble MR; Sander JW
    Epilepsia; 2007 Dec; 48(12):2322-6. PubMed ID: 17711462
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term effects of levetiracetam and topiramate in clinical practice: A head-to-head comparison.
    Bootsma HP; Ricker L; Diepman L; Gehring J; Hulsman J; Lambrechts D; Leenen L; Majoie M; Schellekens A; de Krom M; Aldenkamp AP
    Seizure; 2008 Jan; 17(1):19-26. PubMed ID: 17618131
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient perception of generic antiepileptic drugs in the Midwestern United States.
    Papsdorf TB; Ablah E; Ram S; Sadler T; Liow K
    Epilepsy Behav; 2009 Jan; 14(1):150-3. PubMed ID: 18845274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cosmetic side effects of antiepileptic drugs in adults with epilepsy.
    Chen B; Choi H; Hirsch LJ; Moeller J; Javed A; Kato K; Legge A; Buchsbaum R; Detyniecki K
    Epilepsy Behav; 2015 Jan; 42():129-37. PubMed ID: 25513768
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical experience with generic levetiracetam in people with epilepsy.
    Chaluvadi S; Chiang S; Tran L; Goldsmith CE; Friedman DE
    Epilepsia; 2011 Apr; 52(4):810-5. PubMed ID: 21426334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.